Kiyoaki Kobayashi
EisaiTokyo, Japan
18678 RESULTS
EisaiTokyo, Japan
PAPER Soto-Mercado V, Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C
Huber Heights, United States
COMMENT Much has been said on aducanumab already and, as in any scientific debate, opinions differ widely. Unfortunately, as was evident from the FDA hearing, the debate has become polarized, as if it were politics. This is never beneficial to any debate. This sc
MUTATIONS PSEN2 227077809 GRCh37/hg19 rs75733498 C T Exon 9 Point, Silent Coding Unknown, but in silico analysis did not predict a damaging effect (PHRED-scaled CADD = 11.4). Unknown, but associated with increased glucose metabolism in the bilateral fronto-temporo-
MUTATIONS PSEN1 73686944 GRCh37/hg19 rs7523 G A Exon 12, 3' UTR Point Non-Coding Unknown Unknown, associated with increased thickness in the inferior frontal and orbitofrontal cortices, and basal ganglia c.*947G>A Alzheimer's Disease: Benign This commo
Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center Amsterdam
London, United Kingdom
PAPER Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P
PAPER Senkevich K, Bandres-Ciga S, Gan-Or Z, Krohn L, International Parkinson's Disease Genomics Consortium (IPDGC)
PAPER Kong G, Ellul S, Narayana VK, Kanojia K, Ha HT, Li S, Renoir T, Cao KL, Hannan AJ
PAPER Robbins R, DiClemente RJ, Troxel AB, Jean-Louis G, Butler M, Rapoport DM, Czeisler CA
PAPER Chowdhury S, Kumar S
PAPER Hansson O, Cullen N, Zetterberg H, Alzheimer’s Disease Neuroimaging Initiative, Blennow K, Mattsson-Carlgren N